Teladoc Health에 대한 매도 수량은 투자자에게 Teladoc Health의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Teladoc Health (NYSE:TDOC) 주식, 공매도 수량 보고

Teladoc Health

Teladoc Health is a virtual health provider with a telehealth platform delivering on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has partnered with employers, health plans, and health systems to offer network access to their members; it has also started to market directly to consumers while expanding its service portfolio.

Earnings

News

Guidance

Health Care

After-Hours Center

Movers

TDOC

텔레닥 헬스(NYSE:TDOC)의 주가는 회사가 분석가 기대치를 뛰어넘는 3분기 재무 결과를 보고한 후 수요일 시간외 거래에서 11% 이상 급등했다.

텔레닥 헬스의 주식은 예상을 넘는 3분기 실적에 시간외 거래에서 11% 이상 급등

Equities

Markets

$BTC

$ETH

ARKF

ARKK

ARKW

COIN

PINS

수요일에 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 어드밴스드 마이크로 디바이시스(NASDAQ:AMD), 핀터레스트(NYSE:PINS), 코인베이스 글로벌(NASDAQ:

아크 인베스트가 AMD 주식을 $47.5백만 그리고 핀터레스트 주식을 $12.7백만 매수

Small Cap

Trading Ideas

원격 의료 회사인 텔레닥 헬스(NYSE:TDOC)는 수요일 시장 마감 후 2분기 재무 결과를 발표했다. 주요 하이라이트는 다음과 같다.

텔라닥 헬스:  엇갈린 2분기 실적과 연간 전망 지침 철회로 주가는급락, 52주 최저치 돌파

Teladoc Health Inc

<p>Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $11.0, a high estimate of $14.00, and a low estimate of $8.00. This current average reflects an increase of 18.41% from the previous average price target of $9.29. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1733320944_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>A clear picture of Teladoc Health's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$13.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$14.00</td>
<td>-</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$12.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Steve Valiquette</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Charles Rhyee</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$10.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$9.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$10.00</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Teladoc Health. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Teladoc Health compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Teladoc Health's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>For valuable insights into Teladoc Health's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TDOC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Teladoc Health analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Teladoc Health</h2>
<p>Teladoc Health is a virtual health provider with a telehealth platform delivering on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has partnered with employers, health plans, and health systems to offer network access to their members; it has also started to market directly to consumers while expanding its service portfolio.</p>
<h3>Teladoc Health: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Teladoc Health's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately <strong>-2.99%</strong>. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Teladoc Health's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-5.2%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>-2.21%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Teladoc Health's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-0.94%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Teladoc Health's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>1.05</strong>.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

Unveiling 8 Analyst Insights On Teladoc Health

<p>Piper Sandler  analyst Jessica Tassan   reiterates Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Overweight and raises the price target from $11 to $13.</p>


Price Target

Reiteration

Piper Sandler Reiterates Overweight on Teladoc Health, Raises Price Target to $13

<p><strong>Teladoc Health's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) short percent of float has fallen 4.62% since its last report. The company recently reported that it has <strong>25.69 million shares sold short</strong>, which is 19.39% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 3.79 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Teladoc Health Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732905912_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Teladoc Health has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Teladoc Health's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Teladoc Health's peer group average for short interest as a percentage of float is 5.33%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

How Is The Market Feeling About Teladoc Health?

Teladoc Health Launches New AI-Capabilities To Enhance Virtual Sitter Solution To Improve Patient Safety

<p>Goldman Sachs  analyst David Roman   initiates coverage on Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Buy rating and announces Price Target of $14.</p>


Initiation

Goldman Sachs Initiates Coverage On Teladoc Health with Buy Rating, Announces Price Target of $14

<p>Deutsche Bank  analyst George Hill   maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Hold and raises the price target from $10 to $12.</p>


Deutsche Bank Maintains Hold on Teladoc Health, Raises Price Target to $12

<p>Barclays  analyst Steve Valiquette   maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Overweight and raises the price target from $10 to $12.</p>


Barclays Maintains Overweight on Teladoc Health, Raises Price Target to $12

<p>TD Cowen  analyst Charles Rhyee   maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Hold and lowers the price target from $9 to $8.</p>


TD Cowen Maintains Hold on Teladoc Health, Lowers Price Target to $8

WIIM

Teladoc Health shares are trading higher after the company reported Q3 earnings and sales that beat analyst estimates.

<p><strong>Teladoc Health Inc </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) shares are moving higher in extended trading Wednesday after the company reported financial results for the third quarter that <a href="https://www.benzinga.com/pressreleases/24/10/g41635843/teladoc-health-reports-third-quarter-2024-results">topped analyst expectations</a>.</p>
<ul>
<li><strong>Q3 Revenue:</strong> $640.51 million, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $631.16 million</li>
</ul>
<ul>
<li><strong>Q3 EPS:</strong> Loss of 19 cents, versus estimates for a loss of 27 cents</li>
</ul>
<p>Total revenue was down 3% on a year-over-year basis. Integrated Care segment revenue was up 2% year-over-year, while BetterHelp segment revenue declined 10% year-over-year. U.S. revenue fell 6% year-over-year, while International revenue grew 15%.</p>
<p>Cash flow from operations totaled $110.2 million in the third quarter. The company said it generated $79 million in free cash flow during the quarter.</p>
<p>&#8220;As we close out 2024, we are moving with urgency and making changes to more effectively leverage our leadership position in the complex and dynamic markets we serve. There is more work ahead of us, and 2025 will be an important repositioning year. Our focus remains on delivering consistent performance and driving long-term shareholder value,&#8221; said <strong>Chuck Divita</strong>, CEO of Teladoc Health.</p>
<p><strong>Guidance: </strong>Teladoc expects fourth-quarter Integrated Care segment revenue to be flat to up 2.5% in the fourth quarter. The company expects full-year Integrated Care segment revenue to grow in the low single digits to mid-single digits.</p>
<p><strong>TDOC Price Action: </strong><a href="https://www.benzinga.com/quote/TDOC" target="_blank" rel="noreferrer noopener">Teladoc shares</a> were up 9.26 % in after-hours, trading at $9.68 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.</p>
<p><strong>Read Next: </strong><br />    • <strong><a href="https://www.benzinga.com/news/earnings/24/10/41637326/meta-platforms-q3-earnings-revenue-beat-eps-beat-daily-actives-up-5-strong-momentum-in-ai">Meta Platforms Q3 Earnings: Revenue Beat, EPS Beat, Daily Actives Up 5%, &#8216;Strong Momentum&#8217; In AI</a></strong></p>
<p><em>Photo: Courtesy of Teladoc.</em></p>


Teladoc Health Q3 Earnings: Revenue Beat, EPS Beat, Shares Jump 10%

<p>Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.27) by 29.63 percent.  The company reported quarterly sales of $640.508 million which beat the analyst consensus estimate of $631.160 million by 1.48 percent.  This is a 2.99 percent decrease over sales of $660.238 million the same period last year.</p>


Earnings Beats

Teladoc Health Q3 2024 GAAP EPS $(0.19) Beats $(0.27) Estimate, Sales $640.508M Beat $631.160M Estimate

<p><strong>Teladoc Health</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-10-30. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Teladoc Health will report an <strong>earnings per share</strong> (EPS) of $-0.27. </p>
<p>Investors in Teladoc Health are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Earnings History Snapshot</h3>
<p>The company's EPS beat by $0.06 in the last quarter, leading to a 8.91% drop in the share price on the following day.</p>
<p>Here's a look at Teladoc Health's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.34</td>
<td>-0.46</td>
<td>-0.21</td>
<td>-0.37</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.28</td>
<td>-0.49</td>
<td>-0.17</td>
<td>-0.35</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-9.0%</td>
<td>-2.0%</td>
<td>-24.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730224943_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Teladoc Health were trading at $9.18 as of October 28. Over the last 52-week period, shares are down 46.1%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<h3>Analyst Observations about Teladoc Health</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Teladoc Health.</p>
<p>The consensus rating for Teladoc Health is Neutral, based on 15 analyst ratings. With an average one-year price target of $10.47, there's a potential 14.05% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of Certara, Schrodinger and Phreesia, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Certara is maintaining an Neutral status according to analysts, with an average 1-year price target of $16.0, indicating a potential 74.29% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Schrodinger, with an average 1-year price target of $27.5, suggesting a potential 199.56% upside.</li>
<li>For Phreesia, analysts project an Buy trajectory, with an average 1-year price target of $29.4, indicating a potential 220.26% upside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
<p>The peer analysis summary outlines pivotal metrics for Certara, Schrodinger and Phreesia, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Teladoc Health</td>
<td>Neutral</td>
<td>-1.53%</td>
<td>$454.38M</td>
<td>-44.19%</td>
</tr>
<tr>
<td>Certara</td>
<td>Neutral</td>
<td>3.17%</td>
<td>$53.50M</td>
<td>-1.20%</td>
</tr>
<tr>
<td>Schrodinger</td>
<td>Neutral</td>
<td>34.51%</td>
<td>$31.34M</td>
<td>-10.94%</td>
</tr>
<tr>
<td>Phreesia</td>
<td>Buy</td>
<td>18.97%</td>
<td>$69.30M</td>
<td>-7.15%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Teladoc Health ranks at the bottom for Revenue Growth and Gross Profit, while it is in the middle for Return on Equity. The company's performance is below average compared to its peers in terms of Revenue Growth and Gross Profit, but it is relatively better in terms of Return on Equity.</p>
<h3>Get to Know Teladoc Health Better</h3>
<p>Teladoc Health is a virtual health provider with a telehealth platform delivering on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has partnered with employers, health plans, and health systems to offer network access to their members; it has also started to market directly to consumers while expanding its service portfolio.</p>
<h3>Financial Insights: Teladoc Health</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Teladoc Health's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately <strong>-1.53%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>-130.39%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Teladoc Health's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-44.19%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Teladoc Health's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-21.36%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>1.06</strong>, Teladoc Health faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<p><a href="https://www.benzinga.com/quote/TDOC/earnings"><strong>To track all earnings releases for Teladoc Health visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Preview Of Teladoc Health's Earnings

<p>The healthcare technology sector is undergoing a transformation, with companies leveraging AI, telemedicine, and digital platforms to innovate the way care is delivered. As demand for more efficient and patient-centric solutions grows, several public companies have emerged as leaders in this space.&nbsp;</p>
<h3>1. Teladoc Health</h3>
<p><strong>Market Cap: $1.4 Billion</strong></p>
<p><strong>Focus Area: Telehealth</strong>&nbsp;</p>
<p>Teladoc Health (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tdoc#NYSE">TDOC</a>) is a household name in telemedicine and virtual care, offering services in over 175 countries. As one of the pioneers of telehealth, Teladoc has continuously innovated its sm&nbsp; &nbsp; ervices, making healthcare more accessible and convenient. Its acquisition of Livongo, a leader in managing chronic conditions through AI and digital tools, has expanded its capabilities to cover a wide range of health conditions, from diabetes to hypertension.</p>
<p>What Teladoc does best is delivering a seamless virtual care experience across multiple specialties. The company also excels at integrating behavioral health services, allowing patients to receive both physical and mental healthcare from the comfort of their homes. Teladoc&rsquo;s robust data analytics and AI capabilities offer personalized treatment plans, making it one of the most comprehensive telehealth platforms available. With the global demand for virtual healthcare services on the rise, Teladoc&rsquo;s long-term growth prospects are strong.</p>
<h3>2. WELL Health Technologies</h3>
<p><strong>Market Cap: $1.1 Billion</strong></p>
<p><strong>Focus Area: Digital Health Solutions&nbsp;</strong></p>
<p>WELL Health Technologies (TSX: WELL) has become a key player in North America&#39;s digital healthcare market. Known for its extensive acquisition strategy, WELL has rapidly expanded its network of clinics and digital healthcare platforms. What sets WELL apart is its ability to integrate physical and virtual care through telemedicine, while also providing digital health solutions to clinics across Canada and the U.S.&nbsp;</p>
<p>WELL&#39;s partnership with Healwell AI is one of its most recent innovations, using AI to enhance clinical workflows, improve diagnosis accuracy, and optimize patient outcomes. This integration of AI into routine care is positioning WELL as a leader in AI-driven healthcare. Its platform also powers Wisp, a digital health solution that focuses on sexual and reproductive health, catering to underserved demographics, which further diversifies WELL&#39;s service offerings. As digital healthcare adoption increases, WELL&rsquo;s growth trajectory looks promising.</p>
<h3>3. Omnicell</h3>
<p><strong>Market Cap: $1.9 Billion</strong></p>
<p><strong>Focus Area: Automation and analytics</strong></p>
<p>Omnicell (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/omcl#NASDAQ">OMCL</a>) is a leader in automated medication management solutions, offering a range of products that streamline pharmacy operations and enhance medication adherence. Its offerings include advanced robotics, software solutions, and AI-powered analytics aimed at improving the accuracy and efficiency of drug dispensing in hospitals and clinics.</p>
<p>What Omnicell excels at is its ability to integrate automation with real-time data analytics. The company&rsquo;s solutions help healthcare providers reduce medication errors, optimize inventory management, and ensure regulatory compliance, ultimately improving patient safety. Omnicell&rsquo;s recent shift toward cloud-based, subscription-driven software services is expected to fuel recurring revenue growth, making it an attractive long-term investment. With automation playing a critical role in the future of healthcare, Omnicell is well-positioned to thrive.</p>
<h3>4. IRadimed Corporation&nbsp;</h3>
<p><strong>Market Cap: $700 Million</strong></p>
<p><strong>Focus Area: MRI-Compatible Devices</strong></p>
<p>IRadimed (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/irmd#NASDAQ">IRMD</a>) is pioneering in the MRI-compatible medical device space, addressing the safety challenges posed by traditional equipment in MRI environments. Their MRI-compatible infusion pumps and patient monitoring systems are designed to function safely without causing electromagnetic interference. This focus on MRI-specific safety is a niche yet crucial aspect of patient care, as it allows for uninterrupted and safer patient management during MRI procedures.</p>
<p>With increased utilization of MRI procedures in diagnostics, IRadimed&rsquo;s specialized products are seeing growing demand. The company is expanding its product lineup and entering new geographic markets, which positions it for sustained growth. IRadimed&rsquo;s focus on high-margin, niche products gives it a competitive advantage, contributing to steady revenue growth and profitability.</p>
<h3>5. Evolent Health Inc.</h3>
<p><strong>Market Cap: $1.3 Billion</strong></p>
<p><strong>Focus Area: Value-Based Care</strong></p>
<p>Evolent Health (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/evh#NYSE">EVH</a>) specializes in helping healthcare providers transition to value-based care models, which prioritize patient outcomes over service volume. By offering integrated clinical and administrative services, Evolent enables providers to focus on patient care while optimizing operational efficiencies. Their unique approach is centered on a data-driven platform called Identifi, which uses predictive analytics to guide care decisions and minimize costly interventions.</p>
<p>With the shift in the U.S. healthcare system towards value-based models, Evolent has positioned itself as a leader in this space. As more healthcare systems adopt this model, Evolent&rsquo;s solutions are likely to be in high demand. The company has been expanding through strategic partnerships and acquisitions, projecting steady revenue growth in the coming years.</p>
<h3>6. CareDx, Inc.</h3>
<p><strong>Market Cap: $520 Million</strong></p>
<p><strong>Focus Area: Transplant Diagnostics</strong></p>
<p>CareDx (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cdna#NASDAQ">CDNA</a>) specializes in providing precision diagnostics for transplant patients, focusing on improving graft survival rates. Their flagship product, AlloSure, is a non-invasive blood test that monitors donor-derived cell-free DNA, enabling early detection of organ rejection. By leveraging genomics and data analytics, CareDx offers a personalized approach that minimizes the need for biopsies and improves patient outcomes.</p>
<p>CareDx is positioned for growth as demand for non-invasive diagnostic solutions rises, particularly in the transplant community. The company is continually enhancing its testing solutions and expanding its presence in international markets. Although competition is intensifying, CareDx&rsquo;s innovative pipeline and established reputation should support long-term growth.</p>
<h3>7. Tactile Systems Technology, Inc.</h3>
<p><strong>Market Cap: $450 Million</strong></p>
<p><strong>Focus Area: Chronic Disease Management</strong></p>
<p>Tactile Medical (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcmd#NASDAQ">TCMD</a>) is addressing the problem of lymphedema and chronic swelling conditions, which often go underdiagnosed and undertreated. Their flagship product, the Flexitouch System, is a pneumatic compression device designed for at-home use, giving patients a non-invasive option for managing their symptoms. The company&#39;s focus on patient education and therapy adherence further differentiates it from competitors.</p>
<p>Tactile Medical has a robust market opportunity, given the growing prevalence of chronic diseases and the increased emphasis on at-home healthcare solutions. Despite recent headwinds due to reimbursement challenges, the company is expanding its product portfolio and expects growth as new regulatory changes potentially improve reimbursement rates.</p>
<h4>Conclusion:</h4>
<p>the healthcare technology sector is experiencing significant transformation driven by advancements in AI, telemedicine, and digital solutions. These innovations are reshaping how care is delivered, making it more efficient and patient-centric. As the demand for enhanced healthcare experiences grows, the industry is poised to improve outcomes and accessibility. Looking toward 2025, the ongoing evolution in this field will be critical in addressing the challenges facing healthcare systems worldwide.</p>
<p class="contributor-disclaimer"><em>This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.</em></p>


CDNA

IRMD

OMCL

TCMD

Future Forward: 7 Groundbreaking Healthcare Technology Companies Poised To Disrupt the Industry By 2025

<p>RBC Capital  analyst Sean Dodge   maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Outperform and raises the price target from $9 to $10.</p>


RBC Capital Maintains Outperform on Teladoc Health, Raises Price Target to $10

<p>Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) has been analyzed by 14 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $10.5, a high estimate of $17.00, and a low estimate of $8.00. Experiencing a 34.38% decline, the current average is now lower than the previous average price target of $16.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1728410417_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>A clear picture of Teladoc Health's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$9.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$10.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$9.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$10.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$10.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Charles Rhyee</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$9.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$9.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Steve Valiquette</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>David Grossman</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$9.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$17.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$17.00</td>
<td>$21.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Teladoc Health. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Teladoc Health compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Teladoc Health's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Teladoc Health's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TDOC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Teladoc Health analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering Teladoc Health: A Closer Look</h2>
<p>Teladoc Health is a virtual health provider with a telehealth platform delivering on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has partnered with employers, health plans, and health systems to offer network access to their members; it has also started to market directly to consumers while expanding its service portfolio.</p>
<h3>Teladoc Health: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Teladoc Health's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately <strong>-1.53%</strong>. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Teladoc Health's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-130.39%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-44.19%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-21.36%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>1.06</strong>, caution is advised due to increased financial risk.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Peeling Back The Layers: Exploring Teladoc Health Through Analyst Insights

<p>Evercore ISI Group  analyst Elizabeth Anderson   maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a In-Line and raises the price target from $8 to $9.</p>


Evercore ISI Group Maintains In-Line on Teladoc Health, Raises Price Target to $9

<p><a href="https://www.statnews.com/2024/09/23/addiction-treatment-telehealth-medication-opioid-use-disorder-dea-controlled-substances/#:~:text=A%20new%20bill%20being%20drafted,during%20the%20Covid%2D19%20pandemic.">https://www.statnews.com/2024/09/23/addiction-treatment-telehealth-medication-opioid-use-disorder-dea-controlled-substances/#:~:text=A%20new%20bill%20being%20drafted,during%20the%20Covid%2D19%20pandemic.</a></p>
<p>Two Democratic lawmakers are working to preserve health providers' right to prescribe controlled substances via telehealth, including stimulants for ADHD and buprenorphine for opioid addiction.&nbsp;</p>
<p>A new bill being drafted by Sen. Mark Warner (D-Va.) and Rep. Doris Matsui (D-Calif.) comes months before the expiration of temporary waivers first enacted by the Drug Enforcement Administration's during the Covid-19 pandemic. Though the DEA is currently contemplating new regulations that would roll back many of the pandemic-era flexibilities, the lawmakers' new bill would likely extend the current rules through 2026, according to two lobbyists familiar with the effort.&nbsp;&nbsp;</p>
<p>The flexible rules are set to expire at the end of the year, which telehealth advocates say could threaten patient access to medications, including stimulants for ADHD and common medications used to treat opioid addiction.&nbsp;</p>


Biotech

General

'Lawmakers Push To Let Telehealth Providers Keep Prescribing Stimulants And Addiction Treatment; Flexibility Allowed During Pandemic Is Set To Expire At Year-End' - STAT News

<p>Analysts' ratings for Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) over the last quarter vary from bullish to bearish, as provided by 14 analysts.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $10.57, a high estimate of $17.00, and a low estimate of $8.00. Observing a downward trend, the current average is 35.67% lower than the prior average price target of $16.43. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726603234_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>A comprehensive examination of how financial experts perceive Teladoc Health is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glen Santangelo</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$10.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$9.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$10.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$10.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Charles Rhyee</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$9.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$9.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Steve Valiquette</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>David Grossman</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$9.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$17.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$17.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$10.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Teladoc Health. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Teladoc Health compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Teladoc Health's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Teladoc Health's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TDOC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Teladoc Health analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind Teladoc Health</h2>
<p>Teladoc Health is a virtual health provider with a telehealth platform delivering on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has partnered with employers, health plans, and health systems to offer network access to their members; it has also started to market directly to consumers while expanding its service portfolio.</p>
<h3>Breaking Down Teladoc Health's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Teladoc Health faced challenges, resulting in a decline of approximately <strong>-1.53%</strong> in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Teladoc Health's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-130.39%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Teladoc Health's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-44.19%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Teladoc Health's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-21.36%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Teladoc Health's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>1.06</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Evaluating Teladoc Health: Insights From 14 Financial Analysts

Teladoc Health shares are trading higher after Jefferies raised its price target on the stock from $8 to $10.

<p>Jefferies  analyst Glen Santangelo   maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Hold and raises the price target from $8 to $10.</p>


Jefferies Maintains Hold on Teladoc Health, Raises Price Target to $10

Teladoc (TDOC) Health announced the launch of new AI-enabled capabilities to enhance its Virtual Sitter solution to improve patient safety, address...

Teladoc launches new AI-enabled capabilities for Virtual Sitter solution

Bullish option flow detected in Teladoc (TDOC) with 19,909 calls trading, 3x expected, and implied vol increasing almost 4 points to 73.24%. 11/29 ...

Teladoc call volume above normal and directionally bullish

Teladoc: Maybe This Goose Isn't Cooked Yet (Rating Upgrade)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on BeiGene (BGNE – Research Report) and Teladoc (TDOC – Research Rep...

Analysts Offer Insights on Healthcare Companies: BeiGene (BGNE) and Teladoc (TDOC)

Teladoc: Why I'm Long This Inflection Stock

Teladoc Health, Inc. (TDOC) Piper Sandler 36th Annual Healthcare Conference (Transcript)

Piper Sandler raised the firm's price target on Teladoc (TDOC) to $13 from $11 and keeps an Overweight rating on the shares following a Fireside Ch...

Teladoc price target raised to $13 from $11 at Piper Sandler

Out-of-consensus buy ideas according to Goldman: CAG, TRIP, TDOC

In a report released today, Allen Lutz from Bank of America Securities maintained a Hold rating on Teladoc (TDOC – Research Report). The company's ...

Comments

Teladoc Health

매도 수량

Teladoc Health (NYSE:TDOC) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌